Log In
BCIQ
Print this Print this
 

TRC694 (formerly JNJ-64290694)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionMAP kinase kinase kinase 14 (MAP3K14; NIK) inhibitor
Molecular Target MAP kinase kinase kinase 14 (MAP3K14) (NIK)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies
Regulatory Designation
PartnerTracon Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$155.0M

0

$105.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/28/2016

$155.0M

0

$105.0M

Get a free BioCentury trial today